Clinical Trials Logo

Blood Transfusion, Autologous clinical trials

View clinical trials related to Blood Transfusion, Autologous.

Filter by:
  • None
  • Page 1

NCT ID: NCT03548766 Recruiting - Blood Disease Clinical Trials

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

Transfusion
Start date: September 20, 2018
Phase: Phase 3
Study type: Interventional

A total of 12 subjects will be recruited for participation in this study. 6 subjects will receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a homologous transfusion.

NCT ID: NCT02684747 Completed - Clinical trials for Blood Transfusion, Autologous

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

Start date: February 2016
Phase: Early Phase 1
Study type: Interventional

A total of 40 subjects will be recruited for participation in this study. 20 subjects (10 males and 10 females) will be randomized to the active group (those receiving re-infusion of autologous blood) and 20 subjects (10 males and 10 females) will be randomized to the placebo group (receiving NS infusion).

NCT ID: NCT01226498 Completed - Clinical trials for Blood Transfusion, Autologous

Effects of Blood Transfusion in Healthy Volunteers

Start date: July 2010
Phase: N/A
Study type: Interventional

The objective of this study is to assess effects of the storage of PRBC on endothelial function, inflammation and platelet activation in healthy volunteers

NCT ID: NCT00839241 Completed - Clinical trials for Arthroplasty, Replacement, Knee

A Clinical Study to Investigate if Transfusion of Patients Own Shed Blood Improves the Immunological Status in Comparison to Transfusion of Donor Blood ("Bank Blood")

Start date: January 2009
Phase: N/A
Study type: Interventional

The primary objective of the study is to compare the immunological status after either autologous blood transfusion as administered by Bellovac® ABT or allogenic blood transfusion, with regards to change in Natural Killer (NK) cell frequency in patients undergoing total knee replacement.

NCT ID: NCT00822588 Completed - Clinical trials for Arthroplasty, Replacement, Hip

Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not

Start date: May 2009
Phase: N/A
Study type: Interventional

The study is a prospective, controlled, randomised and assessor blind study that investigate if the need for bank blood transfusion could be reduced in patients, undergoing primary or revision total hip replacement surgery, who receive their own blood back with the medical device Sangvia. A comparison in need for bank blood will be made between patients that either receive their own blood back or not.

NCT ID: NCT00270075 Completed - Blood Transfusion Clinical Trials

A Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery

Start date: January 1990
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether epoetin alfa will enable self-donation of at least 4 units of blood during the 2-week period before surgery (which is a shorter period of time than the conventional 3-week blood donation period before surgery) in patients who are not anemic and who will be undergoing orthopedic or heart and blood vessel surgery. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

NCT ID: NCT00270023 Completed - Blood Transfusion Clinical Trials

A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of epoetin alfa and whether epoetin alfa will enable self-donation of blood during an 11-day period before surgery (which is shorter than the conventional 3-week blood donation period before surgery) in patients who are not anemic and who will be undergoing orthopedic, heart and blood vessel, or breast reduction surgery. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production. Normovolemic hemodilution (NVHD, withdrawal of a patient's blood immediately before surgery, immediate replacement of blood with an equal volume of fluid, and return of the withdrawn blood after completion of surgery; a procedure which reduces the loss of blood during surgery) will also be performed.